Skip to main content

Advertisement

Log in

Recombinant human interferonsα,β andγ reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells

  • Rapid Communication
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

The effects of recombinant human interferons α, β and γ (IFN) on the antiproliferative activity of cytarabine in K562 human myeloid leukaemia clonogenic cells were studied in an agar capillary microassay. The addition of IFN-α did not affect the antiproliferative activity of cytarabine in K562 cultures treated with low concentrations of cytarabine (10–50 nM), whereas in those treated with high concentrations (100–150 nM) IFNα increased the IC50 of cytarabine on day 5 from 102 nM to 214 nM, i.e., cytarabine combined with IFNα was about two-fold less potent than cytarabine alone. Similarly, low concentrations of IFNβ and IFNγ did not affect the antiproliferative activity of cytarabine on K562 colonies, but high concentrations of these two interferons: 4×103 U/ml and 104 U/ml respectively, increased the IC50 of cytarabine on day 5 to 304 nM and to 316 nM respectively, i.e. cytarabine combined with IFNβ or IFNγ was about threefold less potent than cytarabine alone. The evaluation of the present negative interactions of interferons with cytarabine is warranted in fresh cells from myeloid leukaemia patients in primary culture.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abbreviations

IFN:

interferon

References

  • Aul C, Gattermann N, Schneider W (1991) Treatment of advanced myelodysplastic syndromes with recombinant interferon-α2b. Eur J Haematol 46:11–16

    Google Scholar 

  • Beran M, Andersson B, Kantarijian N, Rios A, McCredie KB, Freireich EJ, Gutterman JU (1987) Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure γ interferon. Leukemia 1:52–57

    Google Scholar 

  • Büchner TH, Hiddemann W (1990) Treatment strategies in acute myeloid leukemia (AML): a first line chemotherapy. Blut 60:61–67

    Google Scholar 

  • Catalano L, Majolino I, Musto P, Magrin S, Rotoli B (1988) A trial with α interferon in CMML (abstract). Blut 56:C16

    Google Scholar 

  • Elias L, Crissman HA (1988) Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 48:4868–4873

    Google Scholar 

  • Elias L, Hoffman R, Boswell S, Tensen L, Bonnem, EM (1987) A trial of recombinant α-interferon in the myelodysplastic syndromes. Leukemia 1:105–110

    Google Scholar 

  • Gresser I, Maury C, Belardelli F, Maunoury M-T, Machover D (1988) Effectiveness of mouse interferon α/β compared to single agent chemotherapy in increasing survival time of mice after intravenous inoculation of Friend erythroleukaemia cells. J Natl Cancer Inst 880:126–131

    Google Scholar 

  • Guilhot F, Dreyfus B, Brizard A, Huret JL, Tanzer J (1991) Cytogenetic remissions in chronic myelogenous leukaemia using recombinant human α2b interferon and hydroxyurea with or without low dose cytosine arabinoside. Leuk Lymphoma 4:49–55

    Google Scholar 

  • Hassan HT (1990) In vitro differentiation induction of human normal and leukaemic myeloid progenitor cells. Doctorate (Ph. D.) Thesis in Haematology, University of Cambridge Clinical School, Cambridge, England

    Google Scholar 

  • Hassan HT (1991) In vitro interaction between retinoids and cytokines in human myeloid leukaemia cells. Eur J Cancer 27:1182–1183

    Google Scholar 

  • Hassan HT, Maurer HR (1991a) Synergistic combinations for differentiation therapy of myeloid leukaemia patients. Med Sci Res 19:195–198

    Google Scholar 

  • Hassan HT, Maurer HR (1991b) Effects of recombinant human cytokines on cytarabine activity in K562 human myeloid leukaemia cells. Chemotherapy 37:441–448

    Google Scholar 

  • Hassan HT, Rees JKH (1988) Retinoic acid alone and in combination with cytosine arabinoside induces differentiation of human myelomonocytic and monoblastic leukemic cells. Hematol Oncol 6:39–45

    Google Scholar 

  • Hassan HT, Veit A, Maurer HR (1991) Synergistic interactions between differentiation induction agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic microassay. J Cancer Res Clin Oncol 117:227–231

    Google Scholar 

  • Hosoi T, Ozawa K, Ohta M, Okabe T, Urabe A, Takaku F (1985) Recombinant immune interferon inhibits leukemic cell growth by a monocyte-macrophage-mediated mechanism. Exp Hematol 13:597–602

    Google Scholar 

  • Kafka M, Dvilansky A, Nathan I (1990) Mechanism of interaction between γ interferon and antineoplastic agent on the differentiation of HL-60 promyelocyte leukemia cells. Exp Hematol 18:153–158

    Google Scholar 

  • Kurzrock R, Talpaz M, Kantarijian H, Walters R, Saks S, Trujillo JM, Gutterman JU (1987) Therapy of chronic myelogenous leukemia with human interferon γ. Blood 70:943–947

    Google Scholar 

  • Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukaemia cell line with positive Philadelphia chromosome. Blood 45:321–334

    Google Scholar 

  • Maiolo AT, Cortelezzi A, Calori R, Polli EE (1990) Recombinant human γ interferon as first line therapy for high risk myelodysplastic syndromes. Leukemia 4:480–485

    Google Scholar 

  • Montserrat E, Villamor N, Urbano-Ispizue A, Ribera JM, Lazano M, Vives-Corrons JL, Rozman C (1991) Treatment of early stage-B chronic lymphocytic leukaemia with α-2b interferon after chlorambucil reduction of the tumour mass. Ann Haematol 63:15–19

    Google Scholar 

  • Mowshowitz SL, Chin-Bow ST, Smith GD (1982) Interferon and cis-DDP: combination chemotherapy for P388 leukaemia in CDF1 mice. J Interferon Res 2:587–591

    Google Scholar 

  • Ogawa M, Yoshida Y, Moriyama Y (1988) Phase II clinical trial of recombinant human interferon γ on myelodysplastic syndromes. Third International Congress of Myelodysplasia. Blut 56:c21, 12A

    Google Scholar 

  • Ozer H (1988) Biotherapy of chronic myelogenous leukaemia with interferon. Semin Oncol 15:14–20

    Google Scholar 

  • Rowley PT, Wilhelm BM, Farley BA, LeBalla S (1981) Inducers of erythroid differentiation in K562 human leukemia cells. Exp Hematol 9:32–37

    Google Scholar 

  • Slater LM, Wetzel MW, Cesario T (1981) Combined interferon-antimetabolite therapy of murine L1210 leukemia. Cancer 48:5–9

    Google Scholar 

  • Sutlerland JA, Turner AR, Mannoni P, McGann LE, Ture JM (1986) Differentiation of K562 leukaemic cells along erythroid, nacrophage, granulocyte and megakaryocyte lineages. J Biol Response Mod 5:250–262

    Google Scholar 

  • Tafuri A, Andreeff (1990) Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle specific chemotherapy in vitro. Leukemia 4:826–834

    Google Scholar 

  • Talpaz M, Kantarijian H, Kurzrock R, Trujillo JM, Gutterman JU (1991) Interferon-α produces sustained cytogenetic responses in chronic myeloid leukaemia Philadelphia chromosome positive patients. Ann Intern Med 114:532–537

    Google Scholar 

  • Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies. Cancer Res 50:3473–3486

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maurer, H.R., Hassan, H.T., Tsiriyotis, C. et al. Recombinant human interferonsα,β andγ reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells. J Cancer Res Clin Oncol 118, 329–333 (1992). https://doi.org/10.1007/BF01294435

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01294435

Key words

Navigation